Publications by authors named "L Naver"
Article Synopsis
- A survey was conducted among 32 senior clinicians across 20 European countries to understand current practices in postnatal prophylaxis (PNP) and infant feeding guidelines.
- Twenty-three clinicians responded, revealing that all countries use risk stratification for PNP, but methods and regimens widely differ, with zidovudine being the most commonly used drug.
- There is significant variation in guidelines regarding infant feeding for babies born to HIV-positive parents, highlighting the need for harmonization in policies to minimize HIV transmission and support informed feeding choices.
Article Synopsis
- This study investigates how genetic differences affect efavirenz (EFV) plasma levels in Ugandan children with HIV, especially in relation to therapy success and drug resistance.
- They followed 99 treatment-naïve kids for 24 weeks, measuring EFV levels, HIV viral load, drug resistance, and adherence to medication.
- Results showed significant variation in EFV levels, with a third of samples outside the therapeutic range; genetic factors, particularly being CYP2B6 metabolizers, significantly influenced these concentrations.
Background: Early-life antibiotic exposure is disproportionately high compared to the burden of culture-proven early-onset sepsis (CP-EOS). We assessed the contribution of culture-negative cases to the overall antibiotic exposure in the first postnatal week.
Methods: We conducted a retrospective analysis across eleven countries in Europe, North America, and Australia.
Cytomegalovirus (CMV) infection, which mostly causes a subclinical infection early in life, has important clinical consequences in certain patient groups. CMV is the most common congenital infection and can cause permanent disabilities such as hearing loss and motor- and cognitive deficits in affected infants. In allogeneic haematopoietic stem cell and solid organ transplant recipients, CMV still is an important infectious complication with a risk for life-threatening disease.
View Article and Find Full Text PDFBackground: Efavirenz (EFV) is a drug used to treat HIV. Low plasma concentrations of EFV result in suboptimal viral suppression, whereas high concentrations can cause adverse neuropsychiatric side reactions. Some studies have identified a correlation between the plasma concentrations of EFV metabolites and neurotoxicity.
View Article and Find Full Text PDF